RxDoctor Payments Data

Daniel Becker, MD

Medical Oncology · New York, NYNPI 1639361546

Payments from drug & device makers

$465,958in general payments, 2019–2025

Across 46 payments — averaging $10,130 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$428K
  • E.r. Squibb & Sons, L.L.C.$23K
  • GSK$11K
  • Merck$3K
  • Sanofi$287
  • Amgen$165
  • plus $68 from 1 others

What the payments were for

  • Travel & lodging$16018%
  • Food & beverage$66975%
  • Education$688%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis28$428,194
E.r. Squibb & Sons, L.L.C.2$22,997
GSK4$11,177
Merck5$3,069
Sanofi2$287
Amgen4$165
AstraZeneca1$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$465,958 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$26,235
Medicare patients
57
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →